Abstract
Recent developments in nanotechnology, especially in drug delivery systems, are advanced by featuring novel multifunctional nanoparticles that promise safe, specific, and efficient therapeutic delivery for cancer treatment. Multifunctional nanoparticle-based drug delivery systems enable simultaneous delivery of multiple therapeutic agents for effective combination therapy for cancer. In this chapter, we provide detailed protocols for development and application of a multifunctional nanoparticle system for combinatorial delivery of a chemotherapeutic (cisplatin) and small interfering RNA (siRNA) for human antigen R (HuR) mRNA in cancer cells using a polyamidoamine (PAMAM) dendrimer platform. Protocols for nanoparticle functionalization with folic acid (FA) for targeted delivery of therapeutics toward folate receptor (FR)-overexpressing cancer cells are also described. Further, methods employed for physiochemical and functional characterization of the multifunctional nanoparticle system are discussed in detail. Using the methods described in this chapter, researchers would be able to develop PAMAM dendrimer-based multifunctional nanoparticles for targeted delivery of chemotherapeutics and siRNA combinations. We also provide an example showing the dendrimer-polyethyleneimine-cis-diamminedichloroplatinum-siRNA-folic acid (Den-PEI-CDDP-siRNA-FA) nanoparticle system developed was therapeutically effective toward non-small cell lung cancer (NSCLC) cell lines (H1299 and A549) while exhibiting reduced toxicity to normal lung fibroblast (MRC9) cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ma L, Kohli M, Smith A (2013) Nanoparticles for combination drug therapy. ACS Nano 7:9518–9525. https://doi.org/10.1021/nn405674m
Sonawane R, Harde H, Katariya M et al (2014) Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert Opin Drug Deliv 11:1833–1847. https://doi.org/10.1517/17425247.2014.938634
Cao P, Bae Y (2012) Polymer nanoparticulate drug delivery and combination cancer therapy. Future Oncol 8:1471–1480. https://doi.org/10.2217/fon.12.139
Kydd J, Jadia R, Velpurisiva P et al (2017) Targeting strategies for the combination treatment of cancer using drug delivery systems. Pharmaceutics 9:46. https://doi.org/10.3390/pharmaceutics9040046
Narsireddy A, Vijayashree K, Adimoolam MG et al (2015) Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy. Int J Nanomedicine 10:6865–6878. https://doi.org/10.2147/IJN.S89474
Navath RS, Menjoge AR, Wang B et al (2010) Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications. Biomacromolecules 11:1544–1563. https://doi.org/10.1021/bm100186b
Tekade RK, Kumar PV, Jain NK (2009) Dendrimers in oncology: an expanding horizon. Chem Rev 109:49–87. https://doi.org/10.1021/cr068212n
Xu Z, Kahr M, Walker KL et al (1994) Phenylacetylene dendrimers by the divergent, convergent, and double-stage convergent methods. J Am Chem Soc 116:4537–4550. https://doi.org/10.1021/ja00090a002
Grayson SM, Fréchet JM (2001) Convergent dendrons and dendrimers: from synthesis to applications. Chem Rev 101:3819–3868. https://doi.org/10.1021/cr990116h
Madaan K, Kumar S, Poonia N et al (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 6:139–150. https://doi.org/10.4103/0975-7406.130965
Dufès C, Uchegbu IF, Schätzlein AG (2005) Dendrimers in gene delivery. Adv Drug Deliv Rev 57:2177–2202. https://doi.org/10.1016/j.addr.2005.09.017
Amreddy N, Babu A, Panneerselvam J et al (2017) Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment. Nanomedicine 14:373–384. https://doi.org/10.1016/j.nano.2017.11.010
Acknowledgments
The work was supported in part by a grant received from the National Institutes of Health (NIH), R01 CA167516 (RR), an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences (P20 GM103639) of the National Institutes of Health (RR & AM), VA MERIT grant 101B × 003420 (RR) and by funds received from the Stephenson Cancer Center Seed Grant (RR), Presbyterian Health Foundation Seed Grant (RR), Presbyterian Health Foundation Bridge Grant (RR), and Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics (RR) at the University of Oklahoma Health Sciences Center. Rajagopal Ramesh is an Oklahoma TSET Research Scholar and holds the Jim and Christy Everest Endowed Chair in Cancer Developmental Therapeutics. The authors thank Ms. Kathy Kyler at the office of Vice President for Research, OUHSC, for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Ahmed, R., Amreddy, N., Babu, A., Munshi, A., Ramesh, R. (2019). Combinatorial Nanoparticle Delivery of siRNA and Antineoplastics for Lung Cancer Treatment. In: Dinesh Kumar, L. (eds) RNA Interference and Cancer Therapy. Methods in Molecular Biology, vol 1974. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9220-1_20
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9220-1_20
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9219-5
Online ISBN: 978-1-4939-9220-1
eBook Packages: Springer Protocols